Noxytiolin

Summary

Noxytiolin (CHEMBL2106441) is an approved small molecule (ATC B05CA07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05CA07
• Chemistry: 120.18 Da · C3H8N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106441
Name	Noxytiolin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5251503
ATC	B05CA07
Molecular formula	C3H8N2OS
Molecular weight	120.18
InChIKey	JLMHZVYLAQPMOZ-UHFFFAOYSA-N

SMILES: CNC(=S)NCO

IUPAC name: 1-(hydroxymethyl)-3-methylthiourea

Also known as: Noxitiolina, Noxyflex, Noxyflex 100, Noxyflex-s, Noxyflex-s 100, Noxythiolin, Noxytiolin, Noxytioline, NOXYTIOLIN

Patent coverage: 186 distinct patent families (701 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).